Long-term Safety and Efficacy of GBG Study Participants
About this study
The ETERNITY study is an international, multicenter, observational study that aims to follow up patients who have participated in a GBG trial for early breast cancer, even after the study has officially ended, in order to collect long-term data on survival, late or delayed adverse events, in addition to information related to pregnancy, fertility and other parameters impacting quality of life.
- Condition
- Breast Cancer
- Sponsor
- GBG Forschungs GmbH
Who can join
- Age
- 18 years and older
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 4
- Minimum age: 18 years
- Study condition: Breast Cancer
- Participation and treatment in a GBG clinical trial for early breast cancer.
- Prospective registration: Written informed consent according to local regulatory requirements prior to data and biomaterial collection.
Exclusion 2
- Participation and treatment in a non-GBG clinical trial for early breast cancer.
- Patients with advanced or metastatic breast cancer who have participated and received treatment in a GBG clinical trial.
Where
23 sites, 23 recruiting
MedUni Graz - Med. Universitätsklinik, Klinische Abteilung für Onkologie
Graz, Austria
MedUni Graz - Universitätsklinik für Frauenheilkunde und Geburtshilfe
Graz, Austria
Universitätsklinikum Innsbruck, Klinische Abteilung f. Gynäkologie und Geburt
Innsbruck, Triol, Austria
Ordensklinikum Linz GmbH - BHS
Linz, Austria
LKH Salzburg - PMU
Salzburg, Austria
Medical University of Vienna, Brustambulanz AKH Wien
Vienna, Austria
and 17 more sites on ClinicalTrials.gov
Contact
-
Thomas Ballhausen, Dr.
0049610274800 eternity@gbg.de
Potential match only. Final eligibility is determined by the study team.